Experimental Stargardt Disease Treatment Earns Orphan Drug and Rare Pediatric Disease Designations
source: pixabay.com

Experimental Stargardt Disease Treatment Earns Orphan Drug and Rare Pediatric Disease Designations

According to a story from PR Newswire, the biopharmaceutical company reVision Therapeutics, Inc. has just announced that its experimental therapy REV-0100 has received both Rare Pediatric Disease designation and Orphan…

Continue Reading Experimental Stargardt Disease Treatment Earns Orphan Drug and Rare Pediatric Disease Designations
Experimental Drug Earns Orphan Drug Designation for Polymyositis and Dermatomyositis
source: pixabay.com

Experimental Drug Earns Orphan Drug Designation for Polymyositis and Dermatomyositis

According to a story from Biotech 365, the biotechology company Kezar Life Sciences, Inc. recently announced that its experimental therapy KZR-616 has earned Orphan Drug designations from the US Food…

Continue Reading Experimental Drug Earns Orphan Drug Designation for Polymyositis and Dermatomyositis
Case Report Describes First Known Ocular Myasthenia Gravis Case with COVID-19
source: pixabay.com

Case Report Describes First Known Ocular Myasthenia Gravis Case with COVID-19

According to a story from Myasthenia Gravis News, a recent report describes the first-ever documented case of a patient developing the ocular variant of myasthenia gravis in connection with COVID-19…

Continue Reading Case Report Describes First Known Ocular Myasthenia Gravis Case with COVID-19